Mirum Pharmaceuticals is a leading rare disease company with a global footprint of approved products and a broad pipeline of investigational medicines. On January 26, 2026, Mirum closed on the acquisition of RiverVest portfolio company Bluejay Therapeutics.  Under the terms of the transaction, RiverVst became a shareholder in Mirum.